Furthermore, bortezomib, a specific 26S proteasome inhibitor in phase II clinical trial used to treat endocrine-refractory, metastatic ER+ breast cancer in combination with fulvestrant[76] suppressed growth driven by ESR1-e6>YAP1. The gene discussed is ESR1; the disease is breast cancer.